Abstract library

179 results for "trial".
#1310 Current Trials in Neuroendocrine Tumours: A Systematic Review
Introduction: Trials in neuroendocrine tumours (NETs) have increased markedly in number over the last 10 years. Researchers do not have ready access to a summary of open trials to identify research gaps.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Segelov E, Millican J, Singh S, ...
Keywords: trials, review
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1449 Promoting High Quality Care in Clinical Trials for Patients with Neuroendocrine Tumors (NETs)
Introduction: The European Institute of Oncology is an ENETS Center of Excellence. Many patients (pts) are treated in clinical trials. The clinical research nurse (CRN) is a key figure in care delivery. Optimising staff resources means some trial activities are delivered by nursing staff with limited research experience. To provide high quality care & accurate trial results, all nursing staff caring for NET pts should have appropriate trial related support and training.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Sara Gazzabin
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#1868 Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS)
Introduction: The role of Primary Tumor resection in advanced metastatic NEN is discussed controversely.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr. Nehara Begum
Authors: Begum N, Pavel M, Goretzki P, ...
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#297 Hepatic Arterial Embolization v. Chemoembolization in Patients with Liver Metastases of Digestive Neuroendocrine Tumors
Introduction: Promising results have been reported using hepatic arterial chemoembolization (CE) or embolization (E) alone in patients with liver metastases of DET, but these modalities have not been compared.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski
#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors
Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Jonathan R Strosberg
Authors: Cives M, Kunz P, Nguyen P, Jump H, ...
#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Côme Lepage